The analysis of the pathophysiology of MR activation-mediated diabetic nephropathy and the exploration of its novel therapeutic approaches.

2023 Fiscal Year Final Research Report

• Project/Area Number: 22K20914
• Research Category: Grant-in-Aid for Research Activity Start-up
• Allocation Type: Multi-year Fund
• Review Section: 0903:Organ-based internal medicine and related fields
• Research Institution: Keio University
• Principal Investigator: Nakamura Toshifumi 慶應義塾大学, 医学部(信濃町), 助教 (10594583)
• Project Period (FY): 2022-08-31 – 2024-03-31
• Keywords: 糖尿病腎症 / ミネラルコルチコイド受容体

Outline of Final Research Achievements

Using control mice and diabetic model mice, I evaluated renal damage by staining urine albumin and renal tissues for pathological evaluation and gene expression analysis in renal tissues. In diabetic mice, the development of renal damage such as increased urinary albumin levels, mesangial matrix proliferation, inflammatory changes, and fibrosis over time was confirmed. In addition, I confirmed that the expression of MR target genes was upregulated in the diabetic mice. We have now begun a multifaceted analysis of the effects of continuous administration of MR antagonists to diabetic model mice.

Free Research Field

内分泌学、腎臓学

Academic Significance and Societal Importance of the Research Achievements

本研究の検討により糖尿病性腎症における病理学的特徴や遺伝子発現変動と、MR拮抗薬によるその変動が示された。今後のさらなる詳細な解析が必要であるが、同定された因子・シグナルへの選択的なアプローチを行うことで、選択性と安全性の高い新たな糖尿病性腎症予防・治療法の確立に貢献できることが期待される。ひいては、本研究による成果は糖尿病性腎症による透析導入患者の減少、進行性に増大する医療費の抑制に大きく寄与するものと考えている。